Gapping up
In reaction to earnings/guidance:
- SCSC +5.8% (also announces new $100 mln share repurchase auth), INTU +2% (also increases dividend by 15%), TOL +1.9%, PLAB +1.3%, VNET +1.2%, SCVL +1.2%, RY +0.8%, ATHM +0.5%
Other news:
- BLFS +9.5% (to join S&P SmallCap 600)
- ICLK +8% (board of directors has approved to upsize the share repurchase program announced on December 10, 2020 by $10 mln from $15 mln to $25 mln)
- OPCH +7.7% (to join S&P MidCap 400)
- TRMK +6.9% (to move to S&P SmallCap 600 from S&P MidCap 400)
- MIME +5.2% (to join S&P MidCap 400)
- SJ +3.8% (partners with global friendship exchanges foundation to build a dedicated tech team for artists)
- FGEN +3.2% (topline results from WHITNEY, the Company's Phase 2 clinical study of roxadustat for the treatment of chemotherapy-induced anemia)
- IBIO +3.2% (signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics for RTX-003)
- LMPX +3% (to acquire dealership; expected to add $0.12/sh in 2022)
- GHM +2.9% (awarded over $20 mln in orders to date for 2Q22)
- FLXN +2.6% (expands Phase 1b Trial Investigating FX301)
- CNK +1.8% (to move to S&P SmallCap 600 from S&P MidCap 400)
- AVT +1.5% (increases dividend)
Analyst comments:
- CATB +4.6% (upgraded to Buy from Neutral at H.C. Wainwright)
- OKTA +2.7% (upgraded to Strong Buy from Outperform at Raymond James)
- KRG +2.5% (upgraded to Strong Buy from Outperform at Raymond James)
- UNVR +2.2% (upgraded to Buy from Hold at Berenberg)